Major drugmakers and top agencies alike earned their flowers at the annual Fierce Pharma Marketing Awards gala in ...

Revolut founder Nik Storonsky has for the first time said that the fintech is exploring a dual stock market listing in New ...

the curiosity to learn, the willingness to adapt, the courage to be uncomfortable, and the commitment to solve real human problems will define the true technology change-makers ...

The fact that Gilead Sciences’ Trodelvy failed as a first-line treatm | Newly revealed global phase 3 data from Merck and ...

William Draper III, who brought Harvard Business School savvy to the earliest stirrings of Silicon Valley as a co-founder ...

Nvidia, AMD, and Marvell led chip stock losses Monday after AI CEOs backed slower development. Oracle fell on scrapped share ...

Nvidia, AMD, and Marvell stocks fell sharply Monday as AI leaders called for slower development. Oracle declined while energy stocks rallied on oil surge.

Novartis AG will pay UK biotech Relation Therapeutics Ltd. as much as $1.7 billion to help find drug targets to treat allergic diseases. The deal aims to combine Novartis’s expertise in ...

September Nasdaq 100 E-Mini futures (NQU26) are down -1.77% this morning as chipmakers came under heavy selling pressure ...

GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available ...

The U.S. is drafting rules for biopharma firms investing in China that would likely maintain their ability to ink most licensing deals for Chinese drugs. Read more here.

Recently published Myelodysplastic Syndrome Market Insights report includes a comprehensive understanding of current ...